MedTrace Logo

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

NCT05235516 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 636

Last updated 2024-08-13

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer

Conditions

  • Locally Advanced Cervical Carcinoma

Interventions

DRUG

AK104

q3w iv

RADIATION

EBRT

45-50.4Gy

RADIATION

BT

≥80Gy

DRUG

cisplatin

qw iv

DRUG

Placebo

q3w iv

Sponsors & Collaborators

Principal Investigators

  • Jihong Liu, Ph.D · Sun Yat-sen University

  • Yang Xiang, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-21
Primary Completion
2026-05-31
Completion
2029-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05235516 on ClinicalTrials.gov